Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase
about
Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathwaysDynorphin, stress, and depressionThe dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid systemStress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.Increased arachidonic acid-containing phosphatidylcholine is associated with reactive microglia and astrocytes in the spinal cord after peripheral nerve injuryTyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitizationMKK3, an upstream activator of p38, contributes to formalin phase 2 and late allodynia in miceTrigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice.Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinasesRegulation of lens gap junctions by Transforming Growth Factor beta.6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formationInhibition of spinal astrocytic c-Jun N-terminal kinase (JNK) activation correlates with the analgesic effects of ketamine in neuropathic pain.Interactions between the immune and nervous systems in pain.σ1 receptors activate astrocytes via p38 MAPK phosphorylation leading to the development of mechanical allodynia in a mouse model of neuropathic pain.Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury.Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain.Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats.Repeated stress dysregulates κ-opioid receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism.Ligand-directed signalling within the opioid receptor family.Do glial cells control pain?Erbin is required for myelination in regenerated axons after injury.PINK1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced AKT and increased p38 MAPK activation, and downregulation of EGFR.Kinase cascades and ligand-directed signaling at the kappa opioid receptor.Effects of neonatal stress and morphine on kappa opioid receptor signalingMolecular mechanisms of opioid receptor-dependent signaling and behavior.Anticytokine therapy in neuropathic pain management.Partial infraorbital nerve ligation as a model of trigeminal nerve injury in the mouse: behavioral, neural, and glial reactions.Evaluation of the effects of specific opioid receptor agonists in a rodent model of spinal cord injury.Neuron-glia crosstalk gets serious: role in pain hypersensitivity.Glial responses after chorda tympani nerve injury.Large A-fiber activity is required for microglial proliferation and p38 MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal microglial changes after spared nerve injury.Involvement of p38 MAPK in reactive astrogliosis induced by ischemic stroke.Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors.Does the kappa opioid receptor system contribute to pain aversion?The Analgesic Activity of Bestatin as a Potent APN Inhibitor.Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.
P2860
Q24643003-E98A1A99-4707-4E7D-8372-AEE79622B656Q24650168-B49570FB-F888-4F7A-901B-3A36F5307760Q24655164-411FAA19-1790-46A7-B7DB-72293CFC54AEQ24655307-8169826B-6B95-4C62-B2FE-C1574B4F1FE0Q28394918-6CDCAE4D-9225-48D4-9603-E90710AA0A83Q33553754-06FF8AEC-7B82-40A1-A1B3-F22D52BBC6BBQ33573018-373EC500-C994-4241-B6D0-9E747239A155Q33677946-148F0497-40FD-4293-ADCE-7B4F7DB023B0Q33798722-014DFA3F-0885-4804-BE2E-9083493B4353Q33848751-18BD546C-AD8E-41EF-9853-12AA2559FD58Q34284419-7849EA55-8D91-4780-BB84-78BB4948B3D4Q34352249-63A8C1DD-2B1D-4E2B-B1CC-A0847F1D0383Q34550353-AD6E19B5-ACB0-43E0-89A6-27D2EA7554B9Q34799654-9AB9E43D-68EE-4D7E-8768-E1B97B417DFCQ34914351-4FD52803-B9F6-485E-88A3-779099D3DE6DQ35122783-B91B72C5-901E-4F7C-9F35-452A0BD7D998Q35163121-A9A335DF-8FD5-4629-B114-44591BCA14A1Q35338350-57373A27-6072-416B-AE93-35356C476A9DQ35567536-53C9A095-3AA1-4929-9B7D-54B9252062F8Q35609910-9DB42E44-A58A-41C0-AC4C-D926324967F2Q36063259-C40AC719-F252-4C23-A405-D7C7B394714CQ36336789-5E19A3ED-D287-4204-8FDF-E7255A5F3BE5Q36382935-AE055A25-4FFE-423D-87E8-1B9439013C75Q36672341-028697B3-4AE1-4E60-8A26-C79B512B2B03Q36743140-FA611B14-391A-4C92-BEF3-552BFA98B1DCQ36852642-E31236FB-6B96-463F-A342-F1D330F80DA0Q36900733-D9DC1418-B987-403B-A38B-A98B8E91AAE2Q36948685-75FBCD29-B67D-4676-B6A0-9D429C35AACCQ36974487-89E3945D-2552-41A4-A194-11C9C1F5C1B8Q36998861-A6693C0C-11C5-48BF-8114-1C60EA5AFAFFQ37076756-AA51954C-3BFC-4641-A84E-431065C8835BQ37227174-AA74F6F4-25A3-47D8-BE10-5122E0FC8539Q37265977-A5732240-FBEB-488E-A9B7-15A26B84231CQ37276340-1AA733F5-B30F-4263-BE29-321D5C9A8450Q37382431-71B47F7B-1615-4F35-8C5C-7DD4C56CEACCQ37704935-2F8F7F7B-6D66-4981-8DB4-0B08279E0C8DQ38245110-7177D5C2-9270-46C0-9D5A-6FB184A1D627Q38276410-BF7130A0-4A23-4B21-A583-93ABB40AF3F7Q39856924-6B76308C-217B-4F18-85F7-1CE1C405E2B4Q43075530-5A0C8AE0-2437-42E0-BB95-E27D35C48472
P2860
Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@ast
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@en
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@nl
type
label
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@ast
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@en
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@nl
prefLabel
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@ast
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@en
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@nl
P2093
P2860
P3181
P1476
Sciatic nerve ligation-induced ...... togen-activated protein kinase
@en
P2093
Charles Chavkin
Danielle L Ippolito
Michael R Bruchas
P2860
P304
P3181
P356
10.1523/JNEUROSCI.3728-06.2007
P407
P577
2007-03-07T00:00:00Z